Versigent (NYSE:VGNT) Price Target Raised to $56.00 at Wells Fargo & Company

Versigent (NYSE:VGNT) had its price objective increased by analysts at Wells Fargo & Company from $48.00 to $56.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target points to a potential upside of 22.86% from the company’s current price.

Several other brokerages also recently weighed in on VGNT. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Versigent in a research note on Wednesday. Wolfe Research assumed coverage on Versigent in a research note on Thursday, April 30th. They set an “outperform” rating and a $53.00 price objective for the company. Royal Bank Of Canada raised Versigent from a “sector perform” rating to an “outperform” rating and increased their price objective for the stock from $41.00 to $52.00 in a research report on Wednesday. Evercore reissued an “outperform” rating and issued a $60.00 target price on shares of Versigent in a report on Monday, May 18th. Finally, Wall Street Zen upgraded Versigent to a “hold” rating in a research note on Saturday, April 18th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Versigent currently has a consensus rating of “Buy” and an average target price of $51.25.

Versigent Price Performance

VGNT stock traded down $0.22 on Wednesday, hitting $45.58. The company’s stock had a trading volume of 179,073 shares, compared to its average volume of 2,068,530. The firm’s 50 day simple moving average is $43.38. Versigent has a 1 year low of $26.34 and a 1 year high of $50.88.

Versigent (NYSE:VGNT) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.34. The business had revenue of $2.44 billion for the quarter, compared to analysts’ expectations of $2.29 billion.